Jun 4, 2024

Featuring perspectives from Ms Courtney Arn, Dr Floor J Backes, Dr Kathleen N Moore and Ms Jaclyn Shaver, including the following topics:

• Introduction: The Incidence, Pathogenesis and Prognosis of Ovarian Cancer (0:00)
• Genetic Testing for Newly Diagnosed Advanced Ovarian Cancer (11:01)
• The Role of PARP Inhibitor Maintenance for Newly Diagnosed Advanced Ovarian Cancer (19:02)
• Side Effects Associated with PARP Inhibitors (29:58)
• Dosing, Adherence and Other Issues with PARP Inhibitors for Ovarian Cancer (48:29)
• The Potential Role of PARP Inhibitors in Combination with Anti-PD-1/PD-L1 Antibodies for Advanced Ovarian Cancer Management (54:11)
• PARP Inhibitors for Relapsed/Refractory Ovarian Cancer (1:00:36)
• The Current Role of Mirvetuximab Soravtansine for Ovarian Cancer Treatment (1:07:14)
• Toxicities with Mirvetuximab Soravtansine (1:11:53)
• The Incidence and Management of HER2-Positive Ovarian Cancer (1:18:18)

NCPD information and select publications